Cite

    V. Kruse et al.. “Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug–drug interactions.” Journal of clinical pharmacy and therapeutics, vol. 39, n.d., pp. 259–265. http://access.bl.uk/ark:/81055/vdc_100024821804.0x000063